Transporters and drug therapy: implications for drug disposition and disease.
about
Fruit juice inhibition of uptake transport: a new type of food-drug interactionApical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug targetEffects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamicsThe role of transporters in toxicity and diseaseDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryIndividualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesExpression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsExpression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV preventionEffect of drug transporter genotypes on pravastatin disposition in European- and African-American participantsConcentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model.Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimusMice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatumFluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine.Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.Differential gene expression in liver and small intestine from lactating rats compared to age-matched virgin controls detects increased mRNA of cholesterol biosynthetic genes.Impact of OATP transporters on pharmacokinetics.The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavirPharmacogenomics of antimicrobial agents.Alteration of hepatic but not renal transporter expression in diet-induced obese miceRisk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.Clinically significant psychotropic drug-drug interactions in the primary care setting.Application of Caco-2 cell line in herb-drug interaction studies: current approaches and challengesRisk factors for idiosyncratic drug-induced liver injury.Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working GroupInteraction of innovative small molecule drugs used for cancer therapy with drug transporters.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsDifferential expression of several drug transporter genes in HepG2 and Huh-7 cell lines.Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).Evaluation of chinese-herbal-medicine-induced herb-drug interactions: focusing on organic anion transporter 1.Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies.Functional evolution of the pregnane X receptor.Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteersCardiovascular pharmacogenomics: the future of cardiovascular therapeutics?Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.
P2860
Q24630998-2C7F5064-FD02-4FEA-B437-C0904CCC2E70Q24655792-F476C658-9FEB-404D-9477-D037B59EE27AQ26998835-6CE39E94-D297-4296-9A14-AD4F903AB75AQ26999452-6B36D97C-5EBB-448F-BFF5-0A05380D88FDQ28081272-C4FBB783-1B5C-4835-B955-D692F2A01AA1Q30571118-322E5C64-ED75-4D1E-982A-AC22B0B9D07DQ30584978-E918745E-C152-438F-907A-EF834E795663Q30614811-28D1F113-13B0-4F72-AAEF-50179CD943E6Q33730375-C312F762-3790-464D-AF7B-1C59294CF5AEQ33737892-5F1AE68F-38EF-4AD6-9621-210562A4D5EDQ33763177-0A9FEEB3-AA7F-4810-97FB-C49B6F3FE4BDQ33769971-EB58CDB1-79FE-40C4-83A7-0B62E58C3438Q33776950-F17BD420-42B2-4571-A2C7-3CC18A52EE3AQ33822460-D7852C78-27D5-49C9-8B3D-0783D36E5418Q33977234-16710112-BC1F-4270-9069-19821793F5D2Q34051713-CAF50893-6338-48CD-8D90-E7A1FE957946Q34058706-50DC0EC9-081C-42EF-AFAA-CF5D3456FBD4Q34485100-951907BA-FA7C-4764-837B-2A94D53CA262Q34556733-1019E702-C23B-4C0A-99D5-41DDC686351AQ34607935-9864E953-E618-414B-8E18-ECBD175E7392Q34612244-36570FBF-E275-40B3-A5EB-7D604F3B300BQ34631971-EC27AC64-A522-4844-B6A0-B2BA7F2A4F64Q34973838-450F4416-BB17-430B-B1D0-BB7893D2319AQ34977413-97EFFCAF-7402-4C40-89FE-5FECA3AD06E6Q35002476-F554199E-705C-4761-8FAD-F73B6409A68FQ35088420-BE41A3B3-5BC8-411B-A42C-17B4E048B440Q35104220-C1A25AC4-937C-4AF3-A765-2296841491FFQ35164876-5AB958B8-9CAD-4C71-BEDE-0C949CEA6FA3Q35168108-31639C01-49A6-4EEF-9673-CDA48B9E48DDQ35667919-414A4340-EA74-4698-92DA-E5F2D854D6CFQ35708124-A282EF6B-9CA2-4975-ACC1-9818463DE286Q35915932-C741D78F-1A4E-4190-99F7-D8AE4D3A34FDQ36067365-C01ADAB3-DB7C-4C01-BB0E-8CF94ABA3BD1Q36103626-80B14D2C-9931-46C0-BBED-41ED55772A8BQ36228911-CD304C14-545B-48D4-B4A4-1ADAEEA840EBQ36306228-B6E9E9A3-B475-450D-BA8B-6CC5B6C8E667Q36440155-7EBEABF5-BD89-4BF0-A818-2CA28B51D31EQ36475040-E6912977-7F85-4122-A083-3247FDDCF616Q36487290-A1D1FF4E-86C7-4CE3-A7B8-44B755FC367BQ36533306-5B8F847D-BAF9-40FA-A336-0EC4E52FA113
P2860
Transporters and drug therapy: implications for drug disposition and disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Transporters and drug therapy: implications for drug disposition and disease.
@ast
Transporters and drug therapy: implications for drug disposition and disease.
@en
type
label
Transporters and drug therapy: implications for drug disposition and disease.
@ast
Transporters and drug therapy: implications for drug disposition and disease.
@en
prefLabel
Transporters and drug therapy: implications for drug disposition and disease.
@ast
Transporters and drug therapy: implications for drug disposition and disease.
@en
P1476
Transporters and drug therapy: implications for drug disposition and disease.
@en
P2093
Richard B Kim
Richard H Ho
P304
P356
10.1016/J.CLPT.2005.05.011
P407
P577
2005-09-01T00:00:00Z